Arca
Skip to content
Tools
Tools

Label Changes: Ziihera (zanidatamab-hrii)

A drug's label (its prescribing information) is revised many times after approval: new warnings, new uses, new doses. DailyMed keeps every version. Pick a drug to see them all and what changed between any two.

Every version of the Ziihera label DailyMed has published, from Jazz Pharmaceuticals, Inc., and what changed between any two of them, section by section. Current label on DailyMed.

  • Versions on DailyMed: 3
  • Sections changed, version 2 to 3: 13, Including the boxed warning

What changed from version 2 to version 3

Jul 3, 2025 to Aug 27, 2026, as published on DailyMed. Added text is underlined in green, removed text struck through in red.
  1. Boxed warningChanged · 79 words added, 1 removed
  2. Indications and usageChanged · 154 words added, 35 removed
  3. Dosage and administrationChanged · 829 words added, 335 removed
  4. Warnings and precautionsChanged · 1,144 words added, 261 removed
  5. Adverse reactionsChanged · 1,286 words added, 115 removed
  6. Use in specific populationsChanged · 270 words added, 24 removed
  7. DescriptionChanged · 4 words added, 2 removed
  8. Clinical pharmacologyChanged · 377 words added, 235 removed
  9. Clinical studiesChanged · 1,361 words added, 29 removed
  10. How suppliedChanged · 8 words added, 4 removed
  11. Patient counseling informationChanged · 72 words added, 51 removed
  12. Medication guideNew section · 1,065 words added
  13. Patient informationRemoved · 813 removed

Boxed warning

Changed79 words added, 1 removed
WARNING: DIARRHEA AND EMBRYO-FETAL TOXICITY
ZIIHERA, in combination with fluoropyrimidine- and platinum-containing chemotherapy, with or without tislelizumab-jsgr, can cause severe diarrhea, including life threatening and fatal cases. Use antidiarrheal prophylaxis during the first cycle when ZIIHERA is given in combination with these drugs. Manage with antidiarrheals and supportive measures as clinically indicated. Interrupt, reduce the dose or discontinue ZIIHERA based on severity [see Dosage and Administration (2.4), Warnings and Precautions (5.1), Use in Specific Populations (8.5)].
Embryo-Fetal Toxicity: Exposure to ZIIHERA during pregnancy can cause embryo-fetal harm. Advise patients of the risk and need for effective contraception [see Warnings and Precautions ( 5.12 ), Use in Specific Populations (8.1, 8.3)].

Indications and usage

Changed154 words added, 35 removed
1 INDICATIONS AND USAGE
1.1 Gastroesophageal Adenocarcinoma (GEA)
ZIIHERA is indicated for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test [see Dosage and Administration (2.1)].
• ZIIHERA, in combination with fluoropyrimidine- and platinum-containing chemotherapy and tislelizumab-jsgr, is indicated for the first-line treatment of adult patients with HER2-positive (IHC 3+ or IHC 2+/ISH+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, as detected by an FDA-authorized test [see Dosage and Administration (2.1)].
• ZIIHERA, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with HER2-positive (IHC 3+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, as detected by an FDA-authorized test [see Dosage and Administration (2.1)].
1.2 Biliary Tract Cancer (BTC)
ZIIHERA, as a single agent, is indicated for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-authorized test [see Dosage and Administration (2.1)].
This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies (14.2)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Dosage and administration

Changed829 words added, 335 removed
1 unchanged line
2.1 Patient Selection
HER2-Positive Gastroesophageal Adenocarcinoma (GEA)
Select patients for treatment of unresectable orlocally metastaticadvanced biliaryor tractmetastatic cancerGEA based on HER2-positive status (IHC 3+) tumoror specimensIHC 2+/ISH+), as detected by an FDA-approvedauthorized testtests [see Clinical Studies ( 14.1 )] .
Information on FDA-approved tests for HER2 protein expression in biliary tract cancers is available at: http://www.fda.gov/CompanionDiagnostics.
Information on FDA-authorized tests for HER2 protein expression and gene amplification in gastric, gastroesophageal junction, or esophageal adenocarcinoma is available at: http://www.fda.gov/CompanionDiagnostics.
Biliary Tract Cancer (BTC)
Select patients for treatment of unresectable or metastatic biliary tract cancer based on HER2-positive (IHC 3+) tumor specimens, as detected by an FDA-authorized test [see Clinical Studies ( 14.2 )].
Information on FDA-authorized tests for HER2 protein expression in biliary tract cancers is available at: http://www.fda.gov/CompanionDiagnostics.
2.2 Premedications
2.2 Premedications and Important Administration Information
Premedicate all patients 30 to 60 minutes prior to each dose of ZIIHERA to reduce the risk of infusion-related reactions [see Warnings and Precautions ( 5.34) ]:
•Administer acetaminophen, an antihistamine (such as diphenhydramine) and a corticosteroid (such as hydrocortisone).
2.3 Recommended Dosage
Recommended Dosage and Administration
The recommended dosage of ZIIHERA is 20 mg/kg, administered as an intravenous infusion once every 2 weeks until disease progression or unacceptable toxicity.
ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy with or without tislelizumab-jsgr
Antidiarrheal prophylaxis:
•Administer loperamide 4 mg twice daily beginning on Day 1 and continue for at least 7 days during the first cycle of treatment.
•If patients experience Grade 1 or higher diarrhea during the first cycle, continue prophylaxis with loperamide 4 mg twice daily for at least the first 7 days of each subsequent cycle [see Warnings and Precautions (5.1)].
Fluorouracil-containing regimens:
•When ZIIHERA is administered in combination with fluorouracil-containing regimens, administer fluorouracil as an intravenous infusion. Do NOT administer fluorouracil as an intravenous bolus due to the potential increase in diarrhea [see Warnings and Precautions ( 5.1 )].
Missed dose
ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy with or without tislelizumab-jsgr
If a planned dose of ZIIHERA is delayed or missed, administer the dose as soon as possible if 7 days or fewer have passed since the scheduled time. If more than 7 days have passed since the planned dose, withhold ZIIHERA and resume on day 1 of the next cycle.
ZIIHERA as a single agent
If a planned dose of ZIIHERA is delayed or missed, administer the dose as soon as possible; do not wait until the next planned dose. Adjust the administration schedule to maintain a 2-week interval between doses.
2.3 Recommended Dosage
Gastroesophageal Adenocarcinoma (GEA)
Administer ZIIHERA as an intravenous infusion until disease progression or unacceptable toxicity at the recommended dosages presented in Table 1:
Table 1: Dosage recommendations for patients with GEA
Patient body weight | Dosage
< 70 kg: | • 1,800 mg every 3 weeks or • 1,200 mg every 2 weeks
≥ 70 kg: | • 2,400 mg every 3 weeks or • 1,600 mg every 2 weeks
Refer to the Prescribing Information of each of the individual therapeutic agents used in combination with ZIIHERA for additional dosing information. If chemotherapy is discontinued for reasons other than disease progression, treatment with ZIIHERA, and/or tislelizumab-jsgr can continue until disease progression.
Biliary Tract Cancer
The recommended dosage of ZIIHERA is 20 mg/kg, administered as an intravenous infusion once every 2 weeks until disease progression or unacceptable toxicity.
2.4 Dosage Modifications for Adverse Reactions
•The recommended dosage reduction of ZIIHERA for adverse reactions is 15 mg/kg as described in Table 1.
The recommended dosage reduction of ZIIHERA for adverse reactions is described in Table 2. Permanently discontinue ZIIHERA in patients who cannot tolerate an initial dose reduction.
•Permanently discontinue ZIIHERA in patients who cannot tolerate 15 mg/kg.
Table 12: Recommended Dosage ModificationsReductions for Adverse Reactions
Indication | Recommended dosage | Dosage Modification
Gastroesophageal Adenocarcinoma (GEA) | Patient body weight < 70 kg:
1,800 mg every 3 weeks or 1,200 mg every 2 weeks | 1,400 mg every 3 weeks or 900 mg every 2 weeks
Patient body weight ≥ 70 kg:
2,400 mg every 3 weeks or 1,600 mg every 2 weeks | 1,800 mg every 3 weeks or 1,200 mg every 2 weeks
Biliary Tract Cancer (BTC) | 20 mg/kg every 2 weeks | 15 mg/kg every 2 weeks
The recommended dosage modifications and management for adverse reactions for ZIIHERA are described in Table 3.
Table 3: Dosage Modifications for Adverse Reactions
Adverse Reaction | Severity | Treatment Modification
Diarrhea [see Warnings and Precautions (5.1)] | Mild/Moderate (Grade 1 or 2) | •No dosage modification of ZIIHERA is required. •Initiate appropriate medical therapy and monitor as clinically indicated.
Severe (Grade 3) | •Withhold ZIIHERA treatment until severity improves to ≤ Grade 1. •Initiate or intensify appropriate medical therapy and monitor as clinically indicated. •Administer subsequent ZIIHERA treatment at the same dose level or consider a dose reduction. •For recurrent Grade 3 symptoms, withhold ZIIHERA treatment and ensure medical management has been optimized. oResume ZIIHERA treatment at a reduced dose after severity improves to ≤ Grade 1 •Permanently discontinue ZIIHERA for recurrent Grade 3 symptoms that last > 3 days despite optimized medical management.
Life threatening (Grade 4) | •Permanently discontinue ZIIHERA.
Left Ventricular Dysfunction (LVD) [see Warnings and Precautions ( 5.23 )] | Absolute decrease of ≥ 16% points in LVEF from pre-treatment baseline or LVEF ≤< 50% and absolute decrease of ≥ 10% points below pre-treatment baseline | •Withhold ZIIHERA for at least 4 weeks. •Repeat LVEF assessment within 4 weeks. •Resume ZIIHERA treatment within 4 to 8 weeks if LVEF returns to normal limits and the absolute decrease is ≤ 15% points from baseline. •Permanently discontinue ZIIHERA if LVEF has not recovered to within 15% points from pre-treatment baseline.
Confirmed symptomatic congestive heart failure | •Permanently discontinue ZIIHERA.
Infusion-Related Reactions [see Warnings and Precautions ( 5.34 )] | Mild (Grade 1) | •Reduce ZIIHERA infusion rate by 50%. •For subsequent ZIIHERA infusions increase infusion rate gradually to the rate prior to the adverse reaction, as tolerated.
Moderate (Grade 2) | •Stop ZIIHERA infusion immediately. •Treat with appropriate therapy. •Resume ZIIHERA infusion at 50% of previous infusion rate once symptoms resolve. •For subsequent ZIIHERA infusions, increase infusion rate gradually to the rate prior to the adverse reaction, as tolerated.
Severe (Grade 3) | •Stop ZIIHERA infusion immediately. •Promptly treat with appropriate therapy; infusion should not be restarted during the same cycle even if signs and symptoms completely resolve. •Subsequent ZIIHERA infusions should be administered at 50% of previous infusion rate. •Permanently discontinue ZIIHERA for recurrent Grade 3 reaction.
Life threatening (Grade 4) | •Stop ZIIHERA infusion immediately and permanently discontinue. •Promptly treat with appropriate therapy.
Other Adverse Reactions (excluding LVD, IRR and Diarrhea) [see Warnings andAdverse PrecautionsReactions (56.41)] | Mild/Moderate (GradeGrades 1 or /2) | •No dosedosage modification of ZIIHERA is required for ZIIHERA. •Initiate appropriate medical therapy and monitor as clinically indicated.
Severe (Grade 3) | •Withhold ZIIHERA treatment until severity improves to ≤ Grade 1. •Initiate or intensify appropriate medical therapy and monitor as clinically indicated. •Administer subsequent ZIIHERA treatment at the same dose level or consider dose reduction to 15 mg/kg. •For recurrent Grade 3 symptoms, withhold ZIIHERA treatment and ensure medical management has been optimized. oResume ZIIHERA treatment at a reduced dose of 15 mg/kg after severity improves to ≤ Grade 1. oPermanently discontinue ZIIHERA for recurrent Grade 3 symptoms that last > 3 days despite optimized medical management.
Severe (Grade 3) | •Withhold ZIIHERA treatment until severity improves to ≤ Grade 1. •Initiate appropriate medical therapy and monitor as clinically indicated. •Administer subsequent ZIIHERA treatment at the same dose; consider dose reduction if Grade 3 symptoms recur.
Life threatening (Grade 4) | •Permanently discontinue ZIIHERA
Pneumonitis [see Adverse Reactions (6.1)] | Confirmed Grade ≥ 2 | •Permanently discontinue ZIIHERA.
Other Adverse Reactions (excluding LVD, IRR, Diarrhea, and Pneumonitis) [see Adverse Reactions (6.1)] | Mild/Moderate (Grades 1/2) | •No dosage modification is required for ZIIHERA. •Initiate appropriate medical therapy and monitor as clinically indicated.
Severe (Grade 3) | •Withhold ZIIHERA treatment until severity improves to ≤ Grade 1. •Initiate appropriate medical therapy and monitor as clinically indicated. •Administer subsequent ZIIHERA treatment at the same dose; consider dose reduction to 15 mg/kg if Grade 3 symptoms recur.
Life Threateningthreatening (Grade 4) | •Permanently discontinue ZIIHERA, except as noted below. •Initiate appropriate medical therapy and monitor as clinically indicated. •ZIIHERA treatment may be resumed at the same dose level for Grade 4 electrolyte imbalances or laboratory abnormalities that are corrected within 3 days of onset; do not resume until symptoms improve to ≤ Grade 1. •Permanently discontinue ZIIHERA for recurrent Grade 4 electrolyte imbalances or laboratory abnormalities.
2.5 Preparation and Administration Instructions
Administer only as an intravenous infusion after ZIIHERA is reconstituted and diluted.
Reconstitution
1 unchanged line
•Remove the vial(s) from the refrigerator and allow the vial(s) to reach room temperature.
•Reconstitute each 300 mg vial of ZIIHERA with 5.7 mL of Sterile Water for Injection by slowly directing the stream toward the inside of the wall of the vial, to obtain a final concentration of 50 mg/mL in an extractable volume of 6 mL.
•Swirl the vial gently until completely dissolved. Do not shake or vigorously swirl.
1 unchanged line
•Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. The reconstituted product should be a colorless to light yellow, clear to slightly opalescent solution with no visible particles. Discard the reconstituted vial if any discoloration or particulate matter is observed.
•The product does not contain a preservative. Use the reconstituted ZIIHERA solution immediately or store the reconstituted ZIIHERA solution for up to 4 hours, either at room temperature (18°C to 24°C [64°F to 75°F]) or in a refrigerator (2°C to 8ºC8°C [36°F to 46ºF46°F]).
Dilution
•Withdraw the necessary volume for the calculated dose from each vial [see Dosage and Administration (2.3)].
•Slowly add the necessary dose volume to an infusion bag containing 0.9% Sodium Chloride Injection or 5% Dextrose Injection to prepare an infusion solution with a final concentration of the diluted solution between 0.4 mg/mL and 620 mg/mL. Use the least possible volume of diluent necessary, do not exceed a maximum volume of 500 mL.
•Gently invert the infusion bag to mix. Do not shake.
1 unchanged line
•Discard any unused portion left in the vial(s).
•Use the infusion solution immediately upon dilution or store the infusion solution at room temperature (18°C to 24°C [64°F to 75°F]) for up to 12 hours or in the refrigerator (2ºC2°C to 8ºC8°C [36ºF36°F to 46ºF46°F]) for up to 24 hours. oThese time limits include the beginning of reconstitution through the duration of infusion. oIf these specified times are exceeded, discontinue the current infusion bag and prepare a new bag which contains the remaining dosage of ZIIHERA to be infused.
•Compatibility with intravenous administration materials and the infusion solution has been demonstrated in the following materials: oIntravenous (IV) Bag: Polyvinyl chloride (PVC), polyolefin (PO), ethyl vinyl acetate (EVA), polypropylene (PP), and ethylene-propylene copolymer. oInfusion sets: Polyvinyl chloride/ bis (2-ethylhexyl) phthalate (PVC/DEHP)., Polyurethane (PUR), polyethylene-lined (PE-lined), acrylonitrile-butadiene-styrene (ABS). oInline filters: Polyethersulfone solution filter (PES), polyvinylidene fluoride air filter (PVDF). oClosed System Transfer devices: acrylonitrile-butadiene-styrene (ABS), acrylic c-polymercopolymer, polycarbonate (PC), polyisoprene (PI), polyester, polypropylene (PP) polytetrafluoroethylene (PTFE), silicone, and stainless steel (SS).
Administration
•Administer ZIIHERA as an intravenous infusion with a 0.2 or 0.22 micron filter.
•Administer ZIIHERA as an intravenous infusion with a 0.2 or 0.22 micron filter per the recommended infusion durations listed in Table 4.
•Do not administer as an intravenous push or bolus.
•Do not co-administer ZIIHERA and other intravenous drugs through the same intravenous line.
• Administer ZIIHERA first, followed by tislelizumab-jsgr (if included in the regimen), and then chemotherapy when ZIIHERA is given in combination regimens for the treatment of GEA.
Table 24: Recommended ZIIHERA Infusion Durations
Dose | Infusion Duration
First and Second | 120-150 minutes
First | 120 minutes
Third and FourthSecond | 90 minutes, if previous infusions were well-tolerated
Subsequent | 60 minutes, if previous infusions were well-tolerated

Warnings and precautions

Changed1,144 words added, 261 removed
5 WARNINGS AND PRECAUTIONS
5.1 Embryo-Fetal Toxicity
5.1 Diarrhea
ZIIHERA can cause severe diarrhea.
When ZIIHERA is used in combination with fluoropyrimidine- and platinum-containing chemotherapy with or without tislelizumab-jsgr, severe, life threatening, and fatal cases of diarrhea can occur despite loperamide prophylaxis [see Adverse Reactions (6.1), Use in Specific Populations (8.5)]. The risk of severe and life threatening diarrhea is higher when ZIIHERA is administered with chemotherapy and tislelizumab-jsgr, with a higher risk in patients aged 65 years or older compared to younger patients [see Geriatric Use (8.5)]. Advise patients to increase oral fluids, begin antidiarrheals, and notify their healthcare provider immediately if diarrhea occurs [see Patient Counseling Information (17)].
Administer antidiarrheal prophylaxis with loperamide in cycle 1 for all patients receiving ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy with or without tislelizumab-jsgr. Begin loperamide at the first loose stool when ZIIHERA is administered in combination with chemotherapy or as a single agent. Administer fluids, electrolytes, and additional antidiarrheal agents as necessary. When ZIIHERA was used in combination with chemotherapy with or without tislelizumab-jsgr, 9% of patients had a dose reduction of ZIIHERA due to diarrhea and concomitant agents were dose reduced in 22% of patients. Before modifying the dose of ZIIHERA, evaluate, modify or discontinue drug(s) contributing to diarrhea in accordance with their respective prescribing information. Withhold, reduce the dose, or permanently discontinue ZIIHERA based on severity [see Dosage and Administration (2.2, 2.4)].
In a Phase 2 study evaluating ZIIHERA in combination with FOLFOX in patients with GEA, 57% of patients who received a fluorouracil bolus without loperamide prophylaxis (N=14), experienced Grade 3 diarrhea, while 30% of patients who did not receive a fluorouracil bolus but received loperamide prophylaxis (N=10) experienced Grade 3 diarrhea. If treating patients with ZIIHERA in combination with FOLFOX, do not administer the fluorouracil bolus.
Gastroesophageal Adenocarcinoma (GEA)
In Combination with fluoropyrimidine- and platinum-containing chemotherapy and tislelizumab:
When ZIIHERA was used in combination with fluoropyrimidine- and platinum-containing chemotherapy and tislelizumab-jsgr, diarrhea was reported in 85% of 330 patients treated in clinical studies, including Grade 4 (2.1%), Grade 3 (24%), and Grade 2 (31%) events. Fatal outcomes resulting from diarrhea occurred in 1.5% of patients. Diarrhea leading to dose reduction of ZIIHERA occurred in 10% of patients, and permanent discontinuation of ZIIHERA occurred in 3.9% of patients.
In cycle 1, diarrhea at Grade 4 severity occurred in 1.5% and Grade 3 severity occurred in 15% of patients despite use of loperamide prophylaxis. The median time to onset for cycle 1 diarrhea was 6 days and median time to resolution was 18 days.
In Combination with fluoropyrimidine- and platinum-containing chemotherapy:
When ZIIHERA was used in combination with fluoropyrimidine- and platinum-containing chemotherapy, diarrhea was reported in 81% of 395 patients treated in clinical studies, including Grade 4 (1.3%), Grade 3 (20%) and Grade 2 (33%). Diarrhea leading to dose reduction of ZIIHERA occurred in 10% of patients, and permanent discontinuation of ZIIHERA occurred in 1.8% of patients.
In cycle 1, diarrhea at Grade 4 severity occurred in 0.8% and Grade 3 severity occurred in 14% of patients despite use of loperamide prophylaxis. The median time to onset for cycle 1 diarrhea was 6 days and median time to resolution was 18 days.
Biliary Tract Cancer (BTC)
When ZIIHERA was used as a single agent, diarrhea was reported in 49% of 233 patients treated in clinical studies, including Grade 3 (6%) and Grade 2 (17%). Grade 3 diarrhea occurred in 2.6% of patients during cycle 1 of treatment. Of all diarrhea events occurring during the first cycle of treatment, median time to onset was 4 days and median time to resolution was 21 days.
5.2 Embryo-Fetal Toxicity
Based on the mechanism of action, ZIIHERA can cause fetal harm when administered to a pregnant woman. There are no human or animal data on the use of ZIIHERA in pregnancy. In literature reports, use of a HER2-directed antibody during pregnancy resulted in cases of oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death.
Verify the pregnancy status of females of reproductive potential prior to the initiation of ZIIHERA. Advise pregnant women and females of reproductive potential that exposure to ZIIHERA during pregnancy or within 4 months prior to conception can result in fetal harm. Advise females of reproductive potential to use effective contraception while receiving ZIIHERA and for 4 months following the last dose of ZIIHERA.
5.23 Left Ventricular Dysfunction (LVD)
ZIIHERA can cause decreases in left ventricular ejection fraction (LVEF). LVEF declined by greater than 10% and decreased to less than 50% in 4.3% of 233 patients. LVD leading to permanent discontinuation of ZIIHERA was reported in 0.9% of patients. The median time to first occurrence of left ventricular dysfunction was 5.6 months (range: 1.6 to 18.7 months). Left ventricular dysfunction resolved in 70% of patients.
ZIIHERA can cause decreases in left ventricular ejection fraction (LVEF).
Assess LVEF prior to initiation of ZIIHERA and at regular intervals during treatment. Withhold dose or permanently discontinue ZIIHERA based on severity of adverse reactions [see Dosage and Administration (2.4)].
The safety of ZIIHERA has not been established in patients with a baseline ejection fraction that is below 50% [see Dosage and Administration (2.4)].
Gastroesophageal Adenocarcinoma (GEA)
In patients who received ZIIHERA in combination with chemotherapy and tislelizumab-jsgr, LVEF decrease (an absolute decline in LVEF of more than 10%, resulting in a final value below 50%) was observed in 9% of 330 patients. LVD leading to permanent discontinuation of ZIIHERA was reported in 3% of patients. Fatal outcomes due to LVD occurred in one patient (0.3%). The median time to first occurrence of LVD was 6.9 months (range: 1.2 to 29.1 months). Left ventricular dysfunction resolved in 78% of patients.
In patients who received ZIIHERA in combination with chemotherapy, LVEF decrease was observed in 5% of 395 patients. LVD leading to permanent discontinuation of ZIIHERA was reported in 1.0% of patients. The median time to first occurrence of left ventricular dysfunction was 6.0 months (range: 1.4 to 15.0 months). Left ventricular dysfunction resolved in 70% of patients.
Biliary Tract Cancer (BTC)
In patients who received ZIIHERA as a single agent, LVEF decrease was observed in 4.3% of 233 patients. LVD leading to permanent discontinuation of ZIIHERA was reported in 0.9% of patients. The median time to first occurrence of left ventricular dysfunction was 5.6 months (range: 1.6 to 18.7 months). LVD resolved in 70% of patients.
5.34 Infusion-Related Reactions
ZIIHERA can cause infusion-related reactions (IRRs).
Prior to each dose of ZIIHERA, administer premedication to prevent potential IRRs [see Dosage and Administration (2.2)]. Monitor patients for signs and symptoms of IRR during ZIIHERA administration and as clinically indicated after completion of infusion. Have medications and emergency equipment to treat IRRs available for immediate use.
If an IRR occurs, slow or stop the infusion, and administer appropriate medical management. Monitor patients until complete resolution of signs and symptoms before resuming. Permanently discontinue ZIIHERA in patients with recurrent severe or life-threatening IRRs [see Dosage and Administration (2.4)].
Gastroesophageal Adenocarcinoma (GEA)
ZIIHERA can cause infusion-related reactions (IRRs). An IRR was reported in 3122% of 233330 patients treated with ZIIHERA asand achemotherapy singlewith agenttislelizumab-jsgr in clinical studies, including Grade 34 (0.43%), Grade 3 (1.2%), and Grade 2 (2516%) despite use of prophylaxis. IRRs leading to permanent discontinuation of ZIIHERA were reported in 0.43% of patients. IRRs occurred on the first day of dosing in 2817% of patients;. 97Of all patients who experienced IRRs, 60% of IRRsreactions resolved within onethe first day.
Prior to each dose of ZIIHERA, administer premedications to prevent potential IRRs [see Dosage and Administration (2.2)]. Monitor patients for signs and symptoms of IRR during ZIIHERA administration and as clinically indicated after completion of infusion. Have medications and emergency equipment to treat IRRs available for immediate use.
If an IRR occurs, slow, or stop the infusion, and administer appropriate medical management. Monitor patients until complete resolution of signs and symptoms before resuming. Permanently discontinue ZIIHERA in patients with recurrent severe or life-threatening infusion-related reactions [see Dosage and Administration (2.4)].
5.4 Diarrhea
ZIIHERA can cause severe diarrhea [see Adverse Reactions (6.1)].
Diarrhea was reported in 48% of 233 patients treated in clinical studies, including Grade 3 (6%) and Grade 2 (17%). If diarrhea occurs, administer antidiarrheal treatment as clinically indicated. Perform diagnostic tests as clinically indicated to exclude other causes of diarrhea. Withhold or permanently discontinue ZIIHERA based on severity [see Dosage and Administration (2.4)].
An IRR was reported in 24% of 395 patients treated with ZIIHERA and chemotherapy in clinical studies, including Grade 4 (0.3%), Grade 3 (1.5%), and Grade 2 (18%) despite use of prophylaxis. IRRs leading to permanent discontinuation of ZIIHERA were reported in 1.3% of patients. IRRs occurred on the first day of dosing in 22% of patients. Of all patients who experienced IRRs, 83% of reactions resolved within the first day.
Biliary Tract Cancer (BTC)
An IRR was reported in 31% of 233 patients treated with ZIIHERA as a single agent in clinical studies, including Grade 3 (0.4%), and Grade 2 (25%). IRRs leading to permanent discontinuation of ZIIHERA were reported in 0.4% of patients despite use of prophylaxis. IRRs occurred on the first day of dosing in 28% of patients. Of all patients who experienced IRRs, 97% of reactions were resolved within the first day.

Adverse reactions

Changed1,286 words added, 115 removed
1 unchanged line
The following clinically significant adverse reactions are described in greater detail in other sections of the labeling:
•Embyro-Fetal ToxicityDiarrhea [see Warnings and Precautions (5.1)]
•Left Ventricular dysfunction [see Warnings and Precautions (5.2)]
•Embryo-Fetal Toxicity [see Warnings and Precautions ( 5.2) ]
•Infusion-Related Reactions [see Warnings and Precautions (5.3)]
•Left Ventricular Dysfunction [see Warnings and Precautions (5.3 )]
•Diarrhea [see Warnings and Precautions (5.4)]
•Infusion-Related Reactions [see Warnings and Precautions ( 5.4 )]
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Gastroesophageal Adenocarcinoma (GEA)
The pooled safety population of ZIIHERA described in WARNINGS AND PRECAUTIONS, reflects exposure to ZIIHERA in combination with chemotherapy, with or without tislelizumab-jsgr, in 725 patients with GEA from four open-label studies, including HERIZON-GEA-01 (N=605), ZWI-ZW25-201 (N=46), ZWI-ZW25-101 (N=41), and BGB-A317-ZW25-101 (N=33) at doses of 1,800 mg every 3 weeks (< 70 kg), 2,400 mg every 3 weeks (≥ 70 kg), 1,200 mg every 2 weeks (< 70 kg), 1,600 mg every 2 weeks (≥ 70 kg), or other doses.
Among the 330 patients who received ZIIHERA in combination with chemotherapy and tislelizumab-jsgr for GEA, 64% were exposed for 6 months or longer, and 41% were exposed for 1 year or more.
Among the 395 patients who received ZIIHERA in combination with chemotherapy for GEA, 57% were exposed for 6 months or longer, and 34% were exposed for 1 year or more.
Biliary Tract Cancer (BTC)
The pooled safety population of ZIIHERA administered 20 mg/kg intravenously as a single agent, described in WARNINGS AND PRECAUTIONS reflectreflects exposure in 233 patients administered ZIIHERA 20 mg/kg intravenously as a single agent in two single-arm, open-label studies (ZWI-ZW25-101 and HERIZON-BTC-01), which enrolled: 109 patients with biliary tract cancer, and 124 patients with other cancers. Among 233 patients who received ZIIHERA as a single agent, 39% were exposed for 6 months or longer, and 17% were exposed for greater than one year.
Gastroesophageal Adenocarcinoma (GEA) (HERIZON-GEA-01)
The safety of ZIIHERA administered in combination with chemotherapy, with or without tislelizumab-jsgr for the treatment of GEA was evaluated in 901 patients [see Clinical Studies ( 14.1 )].
Patients received ZIIHERA by IV infusion every 3 weeks at 1,800 mg (< 70 kg body weight) or 2,400 mg (≥ 70 kg), with or without tislelizumab-jsgr and an investigator choice of a fluoropyrimidine- and platinum-based chemotherapy (CAPOX or FP) or trastuzumab with CAPOX or FP [see Clinical Studies (14.1)]. Treatment in each arm continued until disease progression or unacceptable toxicity.
ZIIHERA in combination with tislelizumab-jsgr and chemotherapy
Sixty-three percent (63%) of patients were exposed to ZIIHERA for 6 months or longer and 39% 1 year or longer).
Serious adverse reactions occurred in 59% of patients who received ZIIHERA. Serious adverse reactions in > 2% of patients included diarrhea (17%), infusion-related reactions (5%), vomiting (4.8%), hypokalemia (4.4%), acute kidney injury (3.7%), pneumonia (3.7%), nausea (2.4%), decreased appetite (2.4%), and anemia (2.4%). Fatal adverse reactions occurred in 2.4% of patients who received ZIIHERA in combination with tislelizumab-jsgr and chemotherapy include acute kidney injury (N=2), cardiac failure, diarrhea, dehydration, hypovolemic shock and intestinal obstruction (all N=1).
Permanent discontinuation of ZIIHERA occurred in 13% of patients. Adverse reactions that resulted in permanent discontinuation of ZIIHERA in ≥ 1% of patients included diarrhea (4.4%) and ejection fraction decreased (2.7%).
Dosage interruptions of ZIIHERA, excluding temporary interruptions of ZIIHERA infusions due to infusion-related reactions, occurred in 65% of patients. Adverse reactions requiring a dose interruption of ZIIHERA in > 3% of patients, excluding infusion-related reactions, were diarrhea (14%), neutropenia (11%), platelet count decreased (9%), fatigue (7%), ejection fraction decreased (7%), anemia (6%), hypokalemia (4.8%), decreased appetite (4.4%), vomiting (3.4%), and rash (3.1%).
Dosage reductions of ZIIHERA occurred in 14% of patients. The adverse reactions requiring dosage reduction of ZIIHERA in ≥ 1% of patients were diarrhea (10%) and hypokalemia (1.0%).
The most common adverse reactions (≥ 20%) were diarrhea (83%), nausea (56%), decreased appetite (46%), vomiting (44%), hypokalemia (39%), fatigue (37%), rash (36%), peripheral neuropathy (27%), and infusion-related reaction (25%).
ZIIHERA in combination with chemotherapy
Fifty-seven percent (57%) of patients were exposed to ZIIHERA for 6 months or longer and 32% for 1 year or longer.
Serious adverse reactions occurred in 49% of patients who received ZIIHERA. Serious adverse reactions in > 2% of patients included diarrhea (11%), vomiting (3.3%), decreased appetite (2.6%), pneumonia (2.6%), sepsis (2.6%), hypokalemia (2.3%), and nausea (2.3%).
Permanent discontinuation of ZIIHERA occurred in 10% of patients. Adverse reactions that resulted in permanent discontinuation of ZIIHERA in ≥ 1% of patients included ejection fraction decreased (2.0%), infusion-related reaction (1.6%), and diarrhea (1.6%).
Dosage interruptions of ZIIHERA, excluding temporary interruptions of ZIIHERA infusions due to infusion-related reactions, occurred in 56% of patients. Adverse reactions requiring a dose interruption of ZIIHERA, excluding infusion-related reactions, occurring in > 3% of patients were diarrhea (14%), neutropenia (10%), platelet count decreased (10%), anemia (6%), ejection fraction decreased (6%), fatigue (6%), and hypokalemia (3.9%).
Dosage reductions of ZIIHERA occurred in 15% of patients who received ZIIHERA in combination with chemotherapy. Adverse reactions requiring dosage reductions of ZIIHERA in ≥ 1% of patients were diarrhea (11%), decreased appetite (1.0%), and ejection fraction decreased (1.0%).
The most common adverse reactions in patients receiving ZIIHERA in combination with chemotherapy (≥ 20%) were diarrhea (79%), nausea (54%), vomiting (44%), decreased appetite (40%), fatigue (36%), hypokalemia (33%), peripheral neuropathy (32%), infusion-related reaction (25%), and rash (22%).
Table 5 summarizes the adverse reactions in HERIZON-GEA-01.
Table 5: Adverse Reactions (≥ 10%) With an Increased Incidence (≥ 5% Increase in All Grades) in a ZIIHERA-containing arm in HERIZON-GEA-01
Adverse Reaction* | ZIIHERA with chemotherapy and tislelizumab-jsgr N = 294 | ZIIHERA with chemotherapy N = 305 | Trastuzumab with chemotherapy N = 302
All Grades (%) | Grade 3 or 4 (%) | All Grades (%) | Grade 3 or 4 (%) | All Grades (%) | Grade 3 or 4 (%)
Gastrointestinal disorders
Diarrheaa | 83 | 26 | 79 | 21 | 53 | 14
Nausea | 56 | 8 | 54 | 4.3 | 48 | 3.0
Vomitingb | 44 | 6 | 44 | 3.6 | 34 | 4.3
Metabolism and nutrition disorders
Decreased appetite | 46 | 8 | 40 | 7 | 36 | 6
General disorders and administration site conditions
Fatiguec | 37 | 7 | 36 | 7 | 30 | 6
Skin and subcutaneous tissue disorders
Rashd | 36 | 5 | 22 | 2.6 | 25 | 5
Pruritus | 17 | 0.7 | 8 | 0.3 | 3.6 | 0
Injury, poisoning, and procedural complications
Infusion-related reaction | 25 | 1.7 | 25 | 2.3 | 13 | 0.7
Investigations
Ejection fraction decreasede | 12 | 3.1 | 9 | 2.3 | 7 | 1.3
* Graded per CTCAE version 5. a Diarrhea includes colitis, diarrhea, enteritis, enterocolitis and enterocolitis hemorrhagic. b Vomiting includes hematemesis and vomiting. c Fatigue includes asthenia and fatigue. d Rash includes dermatitis, dermatitis acneiform, palmar-plantar erythrodysesthesia syndrome, rash, rash erythematous, rash maculo-papular, rash pustular and urticaria. e Ejection fraction decreased includes cardiac failure, ejection fraction decreased, left ventricular dysfunction and right ventricular failure.
Table 6 summarizes the laboratory abnormalities in HERIZON‑GEA‑01.
Table 6: Laboratory Abnormalities (≥ 30%) with an Increased Incidence (at least 5% of all Grades or 2% Grade 3-4) in a ZIIHERA-containing arm in HERIZON-GEA-01
Laboratory Abnormalities | ZIIHERA with chemotherapy and tislelizumab-jsgr N = 294 | ZIIHERA with chemotherapy N = 305 | Trastuzumab with chemotherapy N = 302
All Grades (%) | Grade 3 or 4 (%) | All Grades (%) | Grade 3 or 4 (%) | All Grades (%) | Grade 3 or 4 (%)
Hematology
Hemoglobin decreased | 97 | 19 | 92 | 16 | 92 | 16
Chemistry
Potassium decreased | 61 | 27 | 56 | 23 | 38 | 12
Blood calcium decreased | 62 | 1.7 | 52 | 1.6 | 56 | 1.7
Aspartate aminotransferase increased | 51 | 4.8 | 46 | 2.3 | 53 | 0.7
Blood magnesium decreased | 42 | 0.3 | 43 | 3 | 24 | 0
Alanine aminotransferase increased | 41 | 3.4 | 38 | 1.6 | 37 | 0
Sodium decreased | 43 | 2 | 35 | 2.3 | 35 | 1
Creatinine increased | 34 | 4.1 | 23 | 2.6 | 21 | 2.3
Biliary Tract Cancer
Biliary Tract Cancer (HERIZON-BTC-01)
The safety of ZIIHERA was evaluated in 80 patients with previously treated, unresectable or metastatic HER2-positive biliary tract cancer who received at least one prior gemcitabine-containing chemotherapy regimen in HERIZON-BTC-01 [Seesee Clinical Studies ( 14.2 )]. Patients received ZIIHERA 20 mg/kg by IV infusion once every 2 weeks until disease progression or unacceptable toxicity. The median duration of exposure to ZIIHERA was 5.6 months (range: 0.5 to 27.2 months).
Serious adverse reactions occurred in 5354% of patients who received ZIIHERA. Serious adverse reactions in > 2% of patients included biliary obstruction (15%), biliary tract infection (8%), sepsis (8%), pneumonia (5%), diarrhea (3.8%), gastric obstruction (3.8%), and fatigue (2.5%). A fatal adverse reaction of hepatic failure occurred in one patient who received ZIIHERA.
Permanent discontinuation due to an adverse reaction occurred in 2.5% of patients who received ZIIHERA. Adverse reactions which resulted in permanent discontinuation in ≥ 1% of patients who received ZIIHERA included decreased ejection fraction and pneumonitis.
Dosage interruptions due to an adverse reactionreactions, excluding temporary interruptions of ZIIHERA infusions due to infusion-related reactions, occurred in 41% of patients who received ZIIHERA. The most frequent adverse reactions (> 2% of patients) that required dosage interruption were diarrhea, increased alanine aminotransferase, increased aspartate aminotransferase, decreased ejection fraction, pneumonia, cholangitis, fatigue, biliary obstruction, abdominal pain, increased blood creatinine, and decreased potassium.
Dosage reductions due to an adverse reaction occurred in 4% of patients who received ZIIHERA. Adverse reactions requiring dosage reductions in > 1% of patients were diarrhea, nausea, and decreased weight.
The most common adverse reactions in patients receiving ZIIHERA (≥ 20%) were diarrhea, infusion-related reaction, abdominal pain, and fatigue.
Table 37 summarizes the adverse reactions that occurred in HERIZON-BTC-01.
Table 3: Adverse Reactions (≥ 15%) in Patients with Unresectable or Metastatic HER2-Positive BTC Receiving ZIIHERA in HERIZON-BTC-01
Table 7: Adverse Reactions (≥ 15%) in HERIZON-BTC-01
Adverse Reaction* | ZIIHERA N=80
| All Grades (%) | Grades 3 or 4 (%)
Gastrointestinal disorders
3 unchanged lines
Vomiting | 15 | 1
Injury, poisoning, and procedural complications
Infusion-related reaction | 35 | 1
5 unchanged lines
Decreased appetite | 16 | 0
* Graded per CTCAE version 5.
a Diarrhea includes diarrhea and enteritis
b Abdominal pain includes abdominal pain and abdominal pain upper
c Fatigue includes asthenia and fatigue
d Rash includes dermatitis, dermatitis acneiform, palmar-plantar erythrodysaesthesia syndrome, rash, rash maculo-papular, and rash pustular
* Graded per CTCAE version 5. a Diarrhea includes diarrhea and enteritis b Abdominal pain includes abdominal pain and abdominal pain upper c Fatigue includes asthenia and fatigue d Rash includes dermatitis, dermatitis acneiform, palmar-plantar erythrodysesthesia syndrome, rash, rash maculo-papular, and rash pustular
Table 48 summarizes the laboratory abnormalities in HERIZON-BTC-01.
Table 48: Laboratory Abnormalities (≥ 30%) that Worsened from Baseline in Patients with Unresectable or Metastatic HER2-Positive BTC Receiving ZIIHERA in HERIZON-BTC-01
Laboratory Abnormalities | ZIIHERA*
| All Grades (%) | Grades 3 or 4 (%)
Hematology | |
Hemoglobin decreased | 88 | 14
Lymphocytes decreased | 44 | 8
Chemistry | |
Lactate dehydrogenase increased | 55 | 0
5 unchanged lines
Potassium decreased | 34 | 5
* The denominator used to calculate the rate varied from 78 to 80 based on the number of patients with a baseline value and at least one post-treatment value.

Use in specific populations

Changed270 words added, 24 removed
9 unchanged lines
Risk Summary
There are no data on the presence of zanidatamab‑hrii in human milk, the effects on the breastfed child, or the effects on milk production. Published data suggest human IgG is present in human milk but does not enter neonatal or infant circulation in substantial amounts. Consider developmental and health benefits of breastfeeding along with the mother’s clinical need for ZIIHERA treatment and any potential adverse effects on the breastfed child from ZIIHERA or from the underlying maternal condition. This consideration should also take into account the ZIIHERA half-life of approximately 2124 days and a washout period of 4 months [see Clinical Pharmacology (12.3)].
8.3 Females and Males of Reproductive Potential
ZIIHERA can cause fetal harm when administered to a pregnant woman [see Warnings and Precautions ( 5.12 ), and Use in Specific Populations (8.1)].
Pregnancy Testing
6 unchanged lines
8.5 Geriatric Use
Gastroesophageal Adenocarcinoma (GEA)
ZIIHERA in combination with tislelizumab-jsgr and chemotherapy
Of the 80302 patients whorandomized receivedto ZIIHERA for unresectablein orcombination metastaticwith biliarychemotherapy tractand cancertislelizumab-jsgr in HERIZON-BTCGEA-01, there were 39139 (4946%) patients 65 years of age and older. Thirty‑sevenOne hundred and six (4635%) were aged 65-74 years old and 233 (311%) were aged 75 years or older [see Clinical Studies (14.1)].
There was a higher incidence of Grade ≥ 3 adverse reactions observed in patients 65 years of age and older (87%) as compared to younger patients (80%). The incidence of Grade 3 or 4 diarrhea was higher in patients 65 years and older (32%) compared to patients younger than 65 years (20%).
There was an increased incidence of fatal adverse reactions in patients 65 years and older (4.4%); including acute kidney injury (N=2), cardiac failure, dehydration, hypovolemic shock and intestinal obstruction (all N=1), compared to younger patients (0.6%), including diarrhea (N=1).
ZIIHERA in combination with chemotherapy
Of 304 patients randomized to ZIIHERA in combination with chemotherapy in HERIZON-GEA-01, there were 130 (43%) patients 65 years of age and older. One hundred (33%) were aged 65-74 years old and 30 (10%) were aged 75 years or older [see Clinical Studies (14.1)].
No overall differences in safety or effectiveness were observed between these patients 65 years of age and older and younger adult patients.
Biliary Tract Cancer
Of the 80 patients who received ZIIHERA for unresectable or metastatic biliary tract cancer in HERIZON-BTC-01 as a single agent, there were 39 (49%) patients 65 years of age and older. Thirty-seven (46%) were aged 65-74 years old and 2 (3%) were aged 75 years or older [see Clinical Studies (14.2)].
No overall differences in safety or effectiveness were observed between patients 65 years of age and older compared to younger adult patients.

Description

Changed4 words added, 2 removed
11 DESCRIPTION
Zanidatamab‑hrii is a humanized, IgGIgG1-like, bispecific HER2-directed antibody. Zanidatamab‑hrii is produced in mammalian (Chinese hamster ovary) cellscell culture via recombinant DNA technology and has a molecular weight of 124.8 kDa.
ZIIHERA (zanidatamab‑hrii) for injection is supplied as a sterile, preservative free, white lyophilized powder that requires reconstitution and dilution for intravenous use. Each single-dose vial of reconstituted product contains 300 mg of zanidatamab‑hrii and the inactive ingredients: polysorbate 20 (0.63 mg), sodium succinate (4.3 mg), succinic acid (4.3 mg), and sucrose (567 mg). Following reconstitution with 5.7 mL Sterile Water for Injection, a solution containing 50 mg/mL zanidatamab‑hrii is produced with a deliverable volume of 6 mL, with pH of 4.6. The resulting solution is diluted and administered by intravenous infusion.

Clinical pharmacology

Changed377 words added, 235 removed
1 unchanged line
12.1 Mechanism of Action
Zanidatamab-hrii is a bispecific HER2-directed antibody that binds to two extracellular sitesdomains 2 (ECD2) and 4 (ECD4) on HER2. BindingSimilar to other HER2-directed antibodies, in vitro binding of zanidatamab-hrii with HER2 causes clustering and results in internalization leading to a reduction of the receptor on the tumor cell surface. Zanidatamab-hrii induces complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP). These mechanisms result in tumor growth inhibition and cell death in vitro and in vivo.
12.2 Pharmacodynamics
Zanidatamab-hrii exposure-response relationships for safety and efficacy and the time course of the pharmacodynamic response arehave unknownnot been fully characterized.
Cardiac Electrophysiology
A mean increase in the QTc interval > 20 ms was notis observedunlikely at the recommended approved recommended dosage.
12.3 Pharmacokinetics
Zanidatamab‑hrii PK parameters are presented as means (percent coefficient of variation) following administration of ZIIHERA 20 mg/kg every 2 weeks after the 7th or later dose unless otherwise indicated.
Zanidatamab‑hrii maximum concentration (Cmax) is 600 (22.2) µg/mL, the lowest measured concentration (Ctrough) is 178 (29.6) µg/mL, and total systemic exposure (AUC0-336h) is 3,976 (22.5) days*µg/mL following administration of ZIIHERA. The Cmax of zanidatamab‑hrii is dose proportional and the total systemic exposure (AUC0-inf) of zanidatamab‑hrii is greater than dose proportional with increasing doses. The mean Ctrough accumulation ratio of zanidatamab‑hrii is approximately 2.4.
Zanidatamab-hrii pharmacokinetics were characterized at steady-state in patients with BTC and GEA at the approved recommended dosages and are presented as mean (coefficient of variation [CV]%) in Table 9.
Table 9: Zanidatamab-hrii steady-state pharmacokinetics in patients with BTC and GEA at the approved recommended dosages
Parameters | ZIIHERA Dosage
1,800 mg /2,400 mg every 3 weeks in patients with GEA (%CV) | 1,200 mg /1,600 mg every 2 weeks in patients with GEA (%CV) | 20 mg/kg every 2 weeks in patients with BTC (%CV)
Cmin (µg/mL) | 176 (39%) | 203 (36%) | 200 (52%)
Cavg (µg/mL) | 319 (27%) | 319 (27%) | 319 (36%)
Cmax (µg/mL) | 783 (20%) | 609 (21%) | 624 (26%)
The Cmax of zanidatamab-hrii is dose proportional and the total systemic exposure (AUC) of zanidatamab-hrii is greater than dose proportional. Steady state was approached after approximately 16 weeks following multiple doses. Zanidatamab-hrii median Ctrough accumulation is 1.8-fold.
Distribution
The volume of distribution of zanidatamab‑hrii is approximately 7.5 (33) L based on the population pharmacokinetic analysis.
Zanidatamab-hrii volume of distribution is 8.1 L (28.4%).
Elimination
The estimated half-life (t1/2) of zanidatamab‑hrii is approximately 21 days with an associated clearance (CL) of 0.012 L/h (27.9) based on the population pharmacokinetic analysis.
Zanidatamab-hrii elimination half-life is 24 days with an apparent clearance (CL) of 0.3 L/day (30%).
Metabolism
1 unchanged line
Specific Populations
No clinically significantmeaningful differences in the pharmacokinetics of zanidatamab-hrii were observed based on age (2422 to 8887 years), sex, body weight (35 to 142 kg), race (White and39%, Asian) 56%, mildor andBlack moderate0.7%), renalcancer impairmenttype, (eGFRcreatinine clearance 30 to 89 mL/min (estimated usingby the CKDCockcroft-EPIGault equation), mild hepatic impairment (total bilirubin ≤ upper limit of normal ([ULN)] and AST > ULN or total bilirubin between 1 andto 1.5 times ULN and any AST), or bodymoderate weighthepatic (35total kgbilirubin 1.5 to 128≤ kg3 ULN and any AST).
The effect of severe renal impairment (eGFR 15 to 29 mL/min), end-stage renal disease (eGFR < 15 mL/min) with or without hemodialysis, and moderate (total bilirubin > 1.5 to ≤ 3 ULN and any AST) or severe (total bilirubin > 3 ULN and any AST) hepatic impairment on the pharmacokinetics of zanidatamab-hrii pharmacokinetics is unknown.
12.6 Immunogenicity
The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies, including those for zanidatamab-hrii or of other zanidatamab products.
In patients who received ZIIHERA at the approved recommended dosages, 3.4% (18/534) of patients developed treatment-emergent anti-zanidatamab antibodies. Of the patients who developed treatment-emergent anti-zanidatamab antibodies, 17% (3/18) also developed neutralizing antibodies.
There is insufficient information to characterize the anti-drug antibody response to zanidatamab‑hrii and the effects of anti-drug antibodies on pharmacokinetics, pharmacodynamics, safety, or effectiveness of zanidatamab‑hrii.
Because of the low occurrence of anti-drug antibodies, the effect of these antibodies on the pharmacokinetics, safety, and efficacy of zanidatamab products is unknown.

Clinical studies

Changed1,361 words added, 29 removed
14 CLINICAL STUDIES
14.1 Gastroesophageal Adenocarcinoma (GEA)
The efficacy of ZIIHERA in combination with fluoropyrimidine- and platinum-based chemotherapy, with or without tislelizumab-jsgr was evaluated for the treatment of GEA in HERIZON-GEA-01 (NCT05152147), a randomized, 3-arm, open-label, active-comparator, global trial in patients with advanced or metastatic HER2-positive GEA, including those with gastric, gastroesophageal junction, and esophageal adenocarcinoma. Eligible patients were those with untreated, unresectable locally advanced/metastatic GEA that was HER2-positive (IHC 3+ or IHC 2+/ISH+) per central testing, an Eastern Cooperative Oncology Group (ECOG) Performance status (PS) 0 or 1, and adequate organ function, including LVEF ≥ 50%. Patients were enrolled regardless of their PD-L1 expression.
Randomization was stratified by geographic region (Asia, EU/North America, or Rest of world), HER2 status per central assessment (3+ IHC staining, 2+ IHC staining with ISH-positivity), and ECOG PS (0, 1). Patients were randomized 1:1:1 to one of three treatment arms:
•Arm A: Trastuzumab 8 mg/kg IV loading dose (Cycle 1 Day 1), and 6 mg/kg IV in subsequent cycles, followed by investigator’s choice of combination therapy of CAPOX or FP for at least 6 cycles.
•Arm B: ZIIHERA 1,800 mg (weight < 70 kg) or 2,400 mg (body weight ≥ 70 kg) IV in combination with CAPOX or FP.
•Arm C: ZIIHERA 1,800 mg (weight < 70 kg) or 2,400 mg (weight ≥ 70 kg) IV + tislelizumab-jsgr 200 mg IV in combination with CAPOX or FP.
CAPOX consisted of oxaliplatin 130 mg/m2 intravenously and capecitabine 1,000 mg/m2 orally for 14 days; FP consisted of cisplatin 80 mg/m2 intravenously and fluorouracil 800 mg/m2/day intravenously for 5 days. All study medications, except oral capecitabine, were administered as an intravenous infusion every 3-week cycle. Treatment with ZIIHERA, with or without tislelizumab-jsgr continued in each arm until disease progression, unacceptable toxicity, or other discontinuation criteria were met.
The dual major efficacy outcome measures were progression-free survival (PFS) assessed by blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) and overall survival (OS). Additional efficacy outcome measures included Objective response rate (ORR) and Duration of Response (DOR) per BICR.
A total of 914 GEA patients were randomized into HERIZON-GEA-01, including 638 patients with gastric adenocarcinoma, 195 patients with a gastroesophageal junction adenocarcinoma, and 81 patients with an esophageal adenocarcinoma. The trial population characteristics were median age 63 years old (range: 21 to 87), 45% of patients were ≥ 65 years old; 79% were male; 55% were Asian, 39% were White, 1.9% were American Indian or Alaskan Native, and for 1.4% race was other or multiple; 84% were Non-Hispanic or Latino, 13% Hispanic/Latino, and for 3.2% ethnicity was unknown or not reported; 41% ECOG PS 0; and 59% ECOG PS 1. Eighty-three percent (83%) of patients had central HER2 IHC 3+ and 17% had central HER2 IHC 2+/ISH+. Eighty-nine percent (89%) of patients received CAPOX and 8.3% received FP.
ZIIHERA in combination with tislelizumab-jsgr and chemotherapy
Efficacy results comparing Arm C and Arm A in the overall population are summarized in Table 10, Figure 1 and Figure 2. Statistically significant improvements in PFS and OS were demonstrated for the comparison of Arm C to Arm A.
Table 10: Efficacy Results in HERIZON-GEA-01 Comparing Arm C and Arm A in the overall population
| Arm C ZIIHERA with chemotherapy and tislelizumab-jsgr N=302 | Arm A Trastuzumab with chemotherapy N=308
Overall Survival | |
Deaths (%) | 134 (44%) | 170 (55%)
Median, monthsa | 26.4 | 19.2
(95% CI)a | (21.5, 30.3) | (16.8, 21.8)
Hazard ratio (95% CI)b | 0.72 (0.57, 0.90)
p-valuec | 0.0043
Progression-Free Survival | |
Number of events (%) | 154 (51%) | 196 (64%)
Median, monthsa | 12.4 | 8.1
(95% CI)a | (9.8, 18.5) | (7.0, 8.9)
Hazard ratio (95% CI)b | 0.63 (0.51, 0.78)
p-valuec | < 0.0001
Objective Response Rate (ORR) | |
ORR (95% CId) | 67% (61, 72) | 63% (57, 68)
Complete response rate | 20% | 12%
Partial response rate | 47% | 50%
Duration of Response (DOR) | N=202 | N=193
Median in months (95% CI)a | 18.9 (12.1, 37.7) | 8.3 (6.8, 10.1)
a Estimates per Kaplan-Meier method; CIs based on Brookmeyer and Crowley method with log-log transformation. b Hazard ratio and 95% CIs were calculated in comparison with treatment arm Trastuzumab + Chemotherapy stratified by geographic region, HER2 status, and ECOG performance status. c The p-values were calculated by stratified log-rank test. d Two-sided 95% exact confidence interval using the Clopper-Pearson method. CI=confidence interval
In pre-specified exploratory analyses comparing Arm C and Arm A in the HER2 IHC3+ population, the PFS HR was 0.54 (95% CI: 0.43, 0.69), with a median 16.1 months (95% CI: 10.9, 22.0) in Arm C and 7.6 months (95% CI: 6.9, 8.5) in Arm A; the OS HR was 0.70 (95% CI: 0.55, 0.91), with a median 27.3 months (95% CI: 22.3, NE) in Arm C and 19.8 months (95% CI: 16.2, 22.8) in Arm A. In the HER2 IHC2+/ISH+ population, the PFS HR was 1.08 (95% CI: 0.65, 1.78), with a median 8.6 months (95% CI: 6.7, 11.1) in Arm C and 10.0 months (95% CI: 6.9, 18.4) in Arm A; the OS HR was 0.83 (95% CI: 0.50, 1.39), with a median 21.5 months (95% CI: 16.0, 26.4) in Arm C and 18.7 months (95% CI: 13.6, 23.1) in Arm A.
ZIIHERA in combination with chemotherapy
Efficacy results comparing Arm B and Arm A in the HER2 IHC3+ population are summarized in Table 11 and Figure 3. A statistically significant improvement in PFS was demonstrated in the overall population comparing Arm B and Arm A; however, an exploratory analysis of PFS in the HER2 IHC2+/ISH+ population showed a HR of 1.73 (95% CI: 1.06, 2.83), with a median of 6.2 months (95% CI: 3.0, 8.5) for Arm B and 10.0 months (95% CI: 6.9, 18.4) for Arm A, indicating that the improvement in the overall population was primarily attributed to the results observed in the subgroup of patients with HER2 IHC3+. OS in the overall population did not achieve statistical significance at the current interim analysis.
Table 11: Efficacy Results in HERIZON-GEA-01 Comparing Arm B and Arm A in Patients with HER2 IHC3+
| Arm B ZIIHERA with chemotherapy N=251 | Arm A Trastuzumab with chemotherapy N=255
Overall Survival* | |
Deaths (%) | 116 (46%) | 138 (54%)
Median, monthsa | 25.5 | 19.8
(95% CI)a | (21.9, 30.3) | (16.2, 22.8)
Hazard ratio (95% CI)b | 0.74 (0.58, 0.95)
Progression-Free Survival | |
Number of events (%) | 125 (50%) | 167 (65%)
Median, monthsa | 14.2 | 7.6
(95% CI)a | (11.7, 16.7) | (6.9, 8.5)
Hazard ratio (95% CI)b | 0.55 (0.43, 0.69)
Objective Response Rate (ORR) | |
ORR (95% CI)c | 71% (64, 76) | 64% (57, 69)
Complete response rate | 19% | 12%
Partial response rate | 51% | 52%
Duration of Response (DOR) | N=177 | N=162
Median in months (95% CI)a | 16.9 (12.8, 25.3) | 8.1 (6.5, 9.8)
a Estimates per Kaplan-Meier method; CIs based on Brookmeyer and Crowley method with log-log transformation. b Hazard ratio and 95% CIs were calculated in comparison with treatment arm Trastuzumab + Chemotherapy stratified by geographic region, HER2 status, and ECOG performance status. c Two-sided 95% exact confidence interval using the Clopper-Pearson method. * Overall survival data was immature at the time of this analysis.
14.2 HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
The efficacy of ZIIHERA was evaluated in 62 patients with HER2-positive (IHC 3+ by central assessment) BTC in Cohort 1 of HERIZON‑BTC‑01 (NCT04466891), an open-label, multicenter, single arm trial in patients with unresectable or metastatic disease. Patients were required to have received at least one prior gemcitabine-containing systemic chemotherapy regimen in the advanced disease setting and adequate cardiac function (defined as LVEF ≥ 50%).
Patients received ZIIHERA 20 mg/kg intravenously every 2 weeks. ZIIHERA was administered until disease progression or unacceptable toxicity. The major efficacy outcome measures were objective response rate (ORR) and duration of response (DOR) as determined by an independent central review (ICR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
The median age was 64 years (range: 38 to 79 years), 47% of patients were age 65 or older; 55% were female; 61% were Asian, 31% were White, 2% were American Indian or Alaskan Native, and for 6% race was unknown or not reported; 89% were Non-Hispanic or Latino, 8% Hispanic/Latino, and for 3% ethnicity was unknown or not reported. All patients had a baseline Eastern Cooperative Oncology Group (ECOG) performance status of 0 (32%) or 1 (68%). Fifty-three percent of patients had gallbladder cancer, 27% had intrahepatic cholangiocarcinoma, and 19% had extrahepatic cholangiocarcinoma. All patients received at least 1 prior line of gemcitabine-based therapy, 31% had 2 prior lines of therapy, and 10% had 3 or more prior lines of therapy for unresectable or metastatic disease.
Efficacy results are summarized in Table 512.
Table 512: Efficacy Results in HERIZON-BTC-01
Efficacy Parameter* | ZIIHERA (N=62)
Objective Response Rate (95% CI) | 52% (39, 65)
Complete response, n (%) | 23 (34.28)
Partial response, n (%) | 3029 (4847)
Duration of Response (DOR) | N=32
Median†, months (95% CI) | 14.9 (7.4, NE24.0)
DOR ≥ 6 months, n (%) ‡ | (1920 59(63)
DOR ≥ 12 months, n (%) ‡ | 14 (44)
*Assessed by independent central review
* Assessed by independent central review † Based on Kaplan-Meier estimate ‡ Based on observed duration of response
† Based on Kaplan-Meier estimate
‡ Based on observed duration of response
NE = not estimable

How supplied

Changed8 words added, 4 removed
1 unchanged line
ZIIHERA is supplied as a sterile, preservative free, white lyophilized powder in a single-dose vial. Each single-dose vial (NDC 68727‑950‑01) contains 300 mg zanidatamab‑hrii. Each carton of ZIIHERA (NDC 68727‑950‑02) contains 2 single-dose vials.
Store in a refrigerator at 2ºC2°C to 8ºC8°C (36ºF36°F to 46ºF46°F) in the original carton until time of reconstitution. Do not freeze.

Patient counseling information

Changed72 words added, 51 removed
17 PATIENT COUNSELING INFORMATION
Advise the patient to read the FDA-approved patient labeling (PatientMedication InformationGuide).
Diarrhea
Advise patients that ZIIHERA can cause severe diarrhea, and that prophylaxis with loperamide is required at treatment initiation when ZIIHERA is given with fluoropyrimidine- and platinum-containing chemotherapy for the treatment of GEA. Advise patients to notify their healthcare provider immediately if they experience new or worsening diarrhea, and to start loperamide with the first loose stool [see Warnings and Precautions (5.1)].
Embryo-Fetal Toxicity
Advise female patients of the potential risk to a fetus. Advise female patients to contact their healthcare provider with a known or suspected pregnancy [see Warnings and Precautions ( 5.12 ), and Use in Specific Populations (8.1)].
Advise females of reproductive potential to use effective contraception during treatment with ZIIHERA and for 4 months following the last dose [see Warnings and Precautions ( 5.12 ), and Use in Specific Populations (8.3)].
Left Ventricular Dysfunction
Advise patients that ZIIHERA can cause cardiac dysfunction and to contact a healthcare provider immediately for signs and symptoms of cardiac dysfunction [see Warnings and Precautions ( 5.23 )].
Infusion-Related Reactions
Advise patients of the risk of infusion-related reactions and to inform a healthcare provider immediately for symptoms of an infusion-related reaction [see Warnings and Precautions ( 5.34 )].
Diarrhea
Advise patients that ZIIHERA can cause diarrhea, which may be severe. Instruct patients how to manage diarrhea, and to contact their healthcare provider for sustained diarrhea that does not respond to supportive care [see Dosage and Administration (2.4), Warnings and Precautions (5.4)].
Distributed by: Jazz Pharmaceuticals, Inc. Palo Alto, CA 94306
2 unchanged lines

Medication guide

New section1,065 words added
MEDICATION GUIDE ZIIHERA® (zye HAYR rah) (zanidatamab-hrii) for injection, for intravenous use
What is the most important information I should know about ZIIHERA? ZIIHERA can cause serious side effects, including: • Diarrhea. Diarrhea during treatment with ZIIHERA can be severe, life threatening, and can lead to death. Diarrhea may cause loss of fluids and body salts (electrolytes). To help prevent or reduce diarrhea during treatment with ZIIHERA, your healthcare provider: owill tell you to drink more fluids. ostart you on an antidiarrheal medicine such as loperamide or other treatment, as needed. omay temporarily stop, reduce your dose or permanently stop treatment with ZIIHERA, or other medicines you take. If you get new or worsening diarrhea, tell your healthcare provider right away and take antidiarrheal medicine as prescribed. Follow all of your healthcare providers instructions to help with your diarrhea. • Harm to your unborn baby. Taking ZIIHERA during pregnancy or within 4 months before pregnancy can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with ZIIHERA. Females who are able to become pregnant: oYour healthcare provider should do a pregnancy test before you start treatment with ZIIHERA. oUse effective birth control (contraception) during treatment with ZIIHERA and for 4 months after the last dose. See “What are the possible side effects of ZIIHERA?” for more information about side effects.
What is ZIIHERA? ZIIHERA is a prescription medicine used to treat adults with: •gastroesophageal cancer (GEA) including gastric cancer, esophageal cancer, and gastroesophageal junction (GEJ) cancer. ZIIHERA is used in combination with fluoropyrimidine-and platinum- containing chemotherapy with or without tislelizumab-jsgr as the first treatment when your GEA: ocannot be removed by surgery or has spread to other parts of your body (metastatic) and oyour tumor tests positive for human epidermal growth factor receptor 2 (HER2 IHC3+ or IHC 2+/ISH+). •biliary tract cancer (BTC) that includes cancer of the bile duct (cholangiocarcinoma) and cancer of the gallbladder. ZIIHERA is used alone when your BTC: ocannot be removed by surgery or has spread to other parts of your body (metastatic), and owas previously treated, and oyour tumor tests positive for human epidermal growth factor receptor 2 (HER2 IHC3+). Your healthcare provider will perform a test to make sure ZIIHERA is right for you. It is not known if ZIIHERA is safe and effective in children.
Before receiving ZIIHERA, tell your healthcare provider about all of your medical conditions, including if you: •have or have had any heart problems. •are breastfeeding or plan to breastfeed. It is not known if ZIIHERA passes into your breastmilk. Talk to your healthcare provider about the best way to feed your baby if you receive treatment with ZIIHERA. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
How should I receive ZIIHERA? •ZIIHERA is given through a vein by an intravenous (IV) infusion over 120 minutes for your first infusions. If you tolerate the first infusion well, your second infusion will be given to you over 90 minutes. Each additional infusion may be given to you over 60 minutes. •ZIIHERA is given every 2 or 3 weeks. •Your healthcare provider: owill give you medicines 30 to 60 minutes before each treatment to help prevent infusion-related reactions or make them less severe owill give you diarrhea medicines during your first cycle of treatment, if you are being treated for GEA omay slow down your infusion, temporarily stop, or permanently stop your treatment with ZIIHERA if you have certain side effects omay do certain tests to check you for side effects owill decide how many treatments you need •If you miss a dose, call your healthcare provider as soon as possible to reschedule your appointment.
What are the possible side effects of ZIIHERA? ZIIHERA can cause serious side effects, including: •See “What is the most important information I should know about ZIIHERA?” • Heart problems that may affect how well your heart pumps blood. Your healthcare provider will check your heart function before and during treatment with ZIIHERA. Tell your healthcare provider right away if you get any of the following signs and symptoms of a heart problem: onew or worsening shortness of breath ofeeling more tired than usual oswelling of your ankles or feet oloss of consciousness oirregular heartbeat osudden weight gain odizziness or feeling light-headed • Infusion-related reactions. Your healthcare provider will check for side effects during your infusions. Tell your healthcare provider right away if you get any of the following symptoms during or after your infusions of ZIIHERA: oshortness of breath or trouble breathing ofever ochills orash oflushing onausea or vomiting odizziness or feeling lightheaded ochest discomfort Other common side effects when ZIIHERA is given in combination with chemotherapy and tislelizumab-jsgr include: •diarrhea •nausea •decreased appetite •vomiting •low levels of blood potassium •feeling tired •numbness, pain, tingling, or burning in your hands or feet •rash •infusion-related reactions Other common side effects when ZIIHERA is given in combination with chemotherapy include: •diarrhea •nausea •vomiting •numbness, pain, tingling, or burning in your hands or feet •decreased appetite •feeling tired •low levels of blood potassium •infusion-related reactions •rash Other common side effects of ZIIHERA when used alone include: •diarrhea •infusion-related reactions •stomach pain •feeling tired Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all of the possible side effects of ZIIHERA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1‑800‑FDA‑1088.
General information about the safe and effective use of ZIIHERA. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your pharmacist or healthcare provider for information about ZIIHERA that is written for health professionals.
What are the ingredients in ZIIHERA? Active ingredient: zanidatamab-hrii Inactive ingredients: polysorbate 20, sodium succinate, succinic acid, and sucrose Distributed by: Jazz Pharmaceuticals, Inc., Palo Alto, CA 94306 Manufactured by: Jazz Pharmaceuticals Ireland Limited Fifth Floor, Waterloo Exchange Waterloo Road, Dublin 4 Dublin, Ireland D04 E5W7 U.S. License No. 2167 For more information, go to www.ZIIHERA.com or call 1‑800‑520‑5568.
This Medication Guide has been approved by the U.S. Food and Drug Administration. | Revised: 08/2026

Patient information

Removed813 removed
PATIENT INFORMATION ZIIHERA (zye HAYR rah) (zanidatamab-hrii) for injection, for intravenous use
What is the most important information I should know about ZIIHERA? ZIIHERA can cause serious side effects, including: • harm to your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with ZIIHERA. oIf you are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with ZIIHERA. oFemales who are able to become pregnant should use birth control (contraception) during treatment with ZIIHERA and for 4 months after the last dose. See “What are the possible side effects of ZIIHERA?” for more information about side effects.
What is ZIIHERA? ZIIHERA is a prescription medicine used to treat adults who have a type of bile duct (cholangiocarcinoma) or gallbladder cancer called biliary tract cancer (BTC), that is human epidermal growth factor receptor 2 (HER2)-positive (IHC 3+). ZIIHERA may be used when your BTC: owas previously treated; ocannot be removed by surgery or has spread to other parts of your body (metastatic). Your healthcare provider will perform a test to make sure ZIIHERA is right for you. It is not known if ZIIHERA is safe and effective in children.
Before receiving ZIIHERA, tell your healthcare provider about all of your medical conditions, including if you: •have or have had any heart problems •are breastfeeding or plan to breastfeed. It is not known if ZIIHERA passes into your breastmilk. Talk to your healthcare provider about the best way to feed your baby if you receive treatment with ZIIHERA. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
How should I receive ZIIHERA? •ZIIHERA is given through a vein by an intravenous (IV) infusion over 120 to 150 minutes for your first and second infusions. If you tolerate the first and second infusions well, your third and fourth infusions may be given to you over 90 minutes. Each additional infusion may be given to you over 60 minutes. •ZIIHERA is given every 2 weeks. •Your healthcare provider: owill give you medicines 30 to 60 minutes before each treatment to help prevent infusion-related reactions or make them less severe omay slow down, temporarily stop, or permanently stop your treatment with ZIIHERA if you have certain side effects omay do certain tests to check you for some side effects owill decide how many treatments you need •If you miss a dose, call your healthcare provider as soon as possible to reschedule your appointment.
What are the possible side effects of ZIIHERA? ZIIHERA can cause serious side effects, including: •See “What is the most important information I should know about ZIIHERA?” • Heart problems that may affect how well your heart pumps blood. Your healthcare provider will check your heart function before and during treatment with ZIIHERA. Call your healthcare provider right away if you get any of the following signs and symptoms of a heart problem: onew or worsening shortness of breath ofeeling more tired than usual oswelling of your ankles or feet oloss of consciousness oirregular heartbeat osudden weight gain odizziness or feeling light-headed • Infusion-related reactions, a common side effect that can happen during treatment with ZIIHERA. Your healthcare provider will check for side effects during your infusions. Tell your healthcare provider right away if you get any of the following symptoms during or after your infusions of ZIIHERA: oshortness of breath or trouble breathing ofever ochills orash oflushing onausea or vomiting odizziness or feeling lightheaded ochest discomfort • Diarrhea, a common side effect during treatment with ZIIHERA that may be severe. Your healthcare provider may prescribe an antidiarrheal medicine or other treatment, as needed. Other common side effects of ZIIHERA include stomach pain and feeling tired. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all of the possible side effects of ZIIHERA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1‑800‑FDA‑1088.
General information about the safe and effective use of ZIIHERA. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your pharmacist or healthcare provider for information about ZIIHERA that is written for health professionals.
What are the ingredients in ZIIHERA? Active ingredient: zanidatamab-hrii Inactive ingredients: polysorbate 20, sodium succinate, succinic acid, and sucrose Distributed by: Jazz Pharmaceuticals, Inc. Palo Alto, CA 94306 Manufactured by: Jazz Pharmaceuticals Ireland Limited Fifth Floor, Waterloo Exchange Waterloo Road, Dublin 4 Dublin, Ireland D04 E5W7 U.S. License No. 2167 For more information, go to www.ZIIHERA.com or call 1‑800‑520‑5568.
This Patient Information has been approved by the U.S. Food and Drug Administration. | Revised: 7/2025

Unchanged: Dosage forms and strengths, Contraindications, Nonclinical toxicology.

Every version

3 versions of set ae5d9425-fae5-4541-a158-150998343348, newest first.
VersionPublished on DailyMedCompareSPL file
3Aug 27, 2026Shown belowDownload .zip
2Jul 3, 2025With version 1Download .zip
1Nov 25, 2024First versionDownload .zip

Read an SPL file

Open an SPL label file

Drop a Structured Product Labeling .xml file, or the .zip DailyMed downloads, to read it as a label. It is read in this browser tab and not uploaded.

Read in this browser tab; nothing is uploaded.

Versions and label text from DailyMed's SPL web services; a version's text is read from its SPL file, so it matches what DailyMed shows. Recent safety-related changes from FDA's Safety-related Labeling Changes database, which covers NDAs and CDER biologics, not generics. Lists refresh daily. DailyMed, National Library of Medicine

About label change history

How to read a comparison

Sections that changed come first, in the order a reviewer reads a label: boxed warning, recent major changes, indications, dosage, contraindications, warnings and precautions, adverse reactions, then the rest. Each shows the changed lines with one unchanged line either side; longer unchanged stretches are folded into a count. Table rows read left to right with cells separated by a bar.

The comparison covers the label text. Images, product data (NDC codes, ingredients, packaging) and formatting are not compared.

Which label is shown

A drug can have several labels: one per brand-name application (Ozempic, Wegovy and Rybelsus are three), and copies from repackagers. For each NDA or BLA the page takes the DailyMed set with the most versions, which is the application holder's. Generic labels are left out; they follow the brand's label.

Frequently asked questions

Where do the versions come from?
DailyMed, the National Library of Medicine's library of labels in Structured Product Labeling (SPL) format. Each time a company submits a revised label, DailyMed publishes it as a new version of the same set and keeps the old ones.
Is a new version a new FDA approval?
Not always. Companies also submit new versions for changes that need no FDA approval first, such as a new address, a new package size or a corrected typo. Safety changes FDA approved are listed in its Safety-related Labeling Changes database, linked below.
Why does the published date differ from the label's revised date?
The published date is when DailyMed posted the version. The label's own revised date, at the end of the highlights, is when the company revised the text, usually a few days to weeks earlier.
How is the comparison made?
Each section is matched by its standard LOINC code, then split into headings, paragraphs, list items and table rows. Lines are aligned with a longest-common-subsequence diff; a removed and an added line that share at least half their words are shown as one edited line with the changed words marked. Curly quotes, dash styles and spacing are ignored.
Is my SPL file uploaded?
No. A file you drop on this page is read in your browser tab and never sent to Arca.
Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.